Horizon Technology Finance and Monroe Capital Support OSSIO with a $50 Million Credit Facility for Continued Growth

Key Terms

senior credit facility financial

A senior credit facility is a large loan or revolving line of credit that a company borrows from banks or lenders and that has first claim on the company’s cash and assets if the business runs into financial trouble. Think of it as the “first in line” debt with stronger repayment priority and usually stricter rules, so investors watch it because its size, cost and covenants affect a company’s cash flow, risk profile and the value of equity and other creditors.

growth capital financial

Growth capital is funding given to an already-operating company to help it expand—such as opening new locations, boosting production, or launching new products—without buying out current owners. Investors care because it aims to accelerate proven businesses to the next level: it can yield bigger returns than steady, mature companies but carries more risk, like putting fuel on a running car to make it go faster rather than building the car from scratch.

orthopedics medical

Orthopedics is the medical specialty focused on diagnosing, treating and preventing problems of the musculoskeletal system — bones, joints, muscles, ligaments and tendons — including surgical repairs and implants. Investors watch orthopedics because demand for joint replacements, trauma devices and spine treatments tends to be steady and tied to aging populations, technology advances and reimbursement rules, making it a predictable revenue area sensitive to regulation, innovation and hospital spending.

orthopedic fixation medical

Orthopedic fixation is the use of implants or devices—such as plates, screws, rods, pins, or external frames—to hold broken bones or surgical repairs in the correct position while they heal, much like scaffolding holds a building in place during construction. For investors, it matters because demand, pricing, regulatory approvals, and technological improvements for these devices directly affect revenue and profit potential for medical-device makers and hospitals that provide surgical care.

bone regeneration medical

Bone regeneration is the process by which the body repairs or replaces damaged bone tissue, sometimes aided by medical treatments like grafts, implants, or biologic drugs. For investors, it matters because successful regeneration technologies can reduce repeat surgeries, shorten recovery times, and create market demand for new medical products—much like a reliable repair crew restoring a broken bridge, improving long-term value and cutting future costs.

FARMINGTON, Conn. & CHICAGO--(BUSINESS WIRE)-- Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), together with Monroe Capital LLC (“Monroe”), today announced the closing of an initial $40 million senior credit facility for Ossio Inc. (“OSSIO”), with an additional $10 million available to support future growth.

Founded in 2014, OSSIO is an orthopedics company committed to transforming the surgical experience for patients, physicians, providers and payors. The company’s vision is to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development and manufacturing in Caesarea, Israel, with commercial operations based in Palmetto, FL.

“We are thrilled to partner with Horizon Technology Finance and Monroe Capital on this growth capital investment. We look forward to executing on our strategy to expand our orthopedic fixation technology globally,” commented Brian Verrier, Chief Executive Officer of OSSIO. “This partnership combines deep healthcare technology expertise with growth capital. Financing from the Horizon and Monroe platform provides the resources needed to accelerate expansion while preserving the company’s mission of transforming the orthopedic experience for patients.”

“We are excited to partner with Brian and the OSSIO team as they broaden their global impact in orthopedic medical technology,” said Paul Seitz, Chief Investment Officer of Horizon. “This investment reflects Horizon’s commitment to supporting innovative, venture growth companies through strategic financing. OSSIO marks another Horizon investment within the Israeli technology ecosystem.”

“Monroe continues to see exceptional innovation emerging from the Israeli life sciences sector, and OSSIO stands out as a leading force in orthopedic and regenerative technology,” said Mark Solovy, Managing Director and Co-Head, Technology Finance Group at Monroe Capital. “Its disruptive, metal-free bone regeneration solutions align directly with our technology finance vertical, and we are proud to support Brian and his team as they globally scale OSSIO’s impact.”

About Horizon Technology Finance

Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity-backed companies and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in Farmington, Connecticut, with a regional office in Pleasanton, California, and investment professionals located throughout the U.S. Monroe Capital is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, opportunistic, structured credit, real estate and equity. To learn more, please visit horizontechfinance.com.

About Monroe Capital

Monroe Capital LLC (“Monroe”) is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, alternative credit solutions, structured credit, real estate and equity. Since 2004, the firm has been successfully providing capital solutions to clients in the U.S. and Canada. Monroe prides itself on being a value-added and user-friendly partner to business owners, management, and both private equity and independent sponsors. Monroe’s platform offers a wide variety of investment products for both institutional and high net worth investors with a focus on generating high quality “alpha” returns irrespective of business or economic cycles. The firm is headquartered in Chicago and has 12 locations throughout the United States, Middle East, Asia and Australia.

Monroe has been recognized by both its peers and investors with various awards including GrowthCap Advisory’s 2025 Top Private Credit Firm List; Inc.’s 2025 Founder-Friendly Investors List; DealCatalyst as the 2025 Most Innovative Private Credit CLO Manager of the Year; Private Debt Investor as the 2024 Lower Mid-Market Lender of the Year, Americas and 2023 Lower Mid-Market Lender of the Decade; Global M&A Network as the 2024 Lower Mid-Markets Lender of the Year, Americas; Korean Economic Daily as the 2022 Best Performance in Private Debt – Mid Cap; Creditflux as the 2021 Best U.S. Direct Lending Fund; and Pension Bridge as the 2020 Private Credit Strategy of the Year. For more information and important disclaimers, please visit www.monroecap.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260211040682/en/

For more information, please contact:

Investor Relations:

ICR

Garrett Edson

ir@horizontechfinance.com

(860) 284-6450

Media Relations:

ICR

Chris Gillick

HorizonPR@icrinc.com

(646) 677-1819

Zia Uddin

Monroe Capital LLC

312-523-2374

zuddin@monroecap.com

Daniel Abramson

Gregory

857-305-8441

dabramson@gregoryagency.com

Source: Monroe Capital and Horizon Technology Finance Corporation